INTRODUCTION:

The pharmaceutical industry has historically faced a paradox: while advances in biology, chemistry, and genomics have expanded opportunities for drug development, the process of bringing a new medicine to market remains prohibitively lengthy, expensive, and uncertain. It is estimated that the average cost of developing a single successful drug can exceed US $1.3 billion, with development times ranging from 6 to 13 years depending on therapeutic area, and an overall approval probability of less than 14% from preclinical stages to market authorization. These challenges highlight an urgent need for transformative tools that can accelerate research and development (R&D), improve efficiency, and increase success rates^1,2.

In recent years, artificial intelligence (AI) and machine learning (ML) have emerged as such transformative tools. AI refers to computational systems designed to mimic or approximate human cognitive functions such as perception, reasoning, and problem-solving. ML, a subset of AI, relies on algorithms that learn patterns from data and improve performance with experience. Within ML, deep learning (DL), inspired by the architecture of the human brain, has gained prominence due to its ability to handle high-dimensional, nonlinear data such as molecular structures, imaging outputs, and clinical trial datasets^3,4,5.

The integration of AI and ML into the pharmaceutical industry has begun to impact multiple stages of the drug development pipeline. In early-stage drug discovery, AI models can screen vast chemical libraries, predict binding affinities, and identify potential therapeutic targets, thereby reducing the need for resource-intensive experimental assays^5,6. AI-enabled molecular design tools can also generate novel compounds with desirable pharmacokinetic and safety profiles, helping to overcome challenges of attrition in lead optimization⁷.

Moving into preclinical and translational research, AI has been applied to predict toxicity, model drug–drug interactions, and analyze omics data for biomarker discovery⁸. In clinical development, AI and ML show increasing potential in trial design, patient recruitment, and adaptive monitoring. For example, AI-driven patient stratification enables identification of subpopulations most likely to benefit from a therapy, thereby improving statistical power and trial efficiency⁹. Furthermore, AI-based natural language processing and real-world data analytics are facilitating integration of electronic health records (EHRs), wearable devices, and digital biomarkers into clinical research. The COVID-19 pandemic further accelerated reliance on digital tools, providing momentum for AI-enabled remote monitoring and decentralized trials¹⁰.

Beyond discovery and development, AI contributes to regulatory science and post-market surveillance, where predictive algorithms support pharmacovigilance, adverse event detection, and lifecycle management of approved drugs¹¹. As such, AI is not only reshaping the efficiency of R&D but also transforming how pharmaceutical companies manage risk, compliance, and patient outcomes throughout the drug lifecycle.

While the potential of AI in the pharmaceutical domain is immense, challenges remain. Issues such as data heterogeneity, algorithmic transparency, model validation, regulatory acceptance, and ethical considerations related to patient privacy and algorithmic bias must be carefully addressed before AI can achieve widespread adoption. Thus, a balanced perspective is necessary: separating the realistic applications of AI from overhyped claims, while fostering interdisciplinary collaboration among data scientists, clinicians, regulators, and industry stakeholders¹². By situating AI within the broader scientific and industrial landscape, we aim to inform optimal strategies for its responsible and effective integration into drug development.

Figure 1 – Phases of Evaluation of Artificial Intelligence

Limitations of Current Method in Drug Discovery and Integration of Ai to Overcome Limitations:

Drug development remains one of the most resource-intensive activities in the pharmaceutical sector. Small molecules have traditionally dominated due to their relatively simple chemical synthesis, lower production costs, and ease of formulation. Their widespread use in therapeutic areas is largely attributed to their stability and the possibility of generating numerous derivatives¹. However, the sector faces growing challenges. Increased competition from generics, stringent regulatory demands, and the requirement for extensive clinical data before approval have escalated both costs and development timelines². As a result, companies are under economic pressure to innovate beyond conventional approaches. Parallel to this, the biomolecular drug industry comprising proteins, peptides, and nucleic acid-based therapeutics has experienced rapid growth¹³. Unlike small molecules, biomacromolecules rely on complex supramolecular conformations for their stability and function, which complicates their pharmacokinetics and delivery. Biologics such as insulin and adalimumab illustrate the clinical success of biomolecules, but their reliance on infusion-based administration and sensitivity to degradation present significant formulation challenges¹⁴. Current research therefore emphasizes pharmacokinetic modulation, stabilization strategies, and delivery innovations, especially for nucleic acid therapies¹⁵.

In addressing these barriers, artificial intelligence (AI) has emerged as a powerful enabler. AI, through its subsets such as machine learning (ML), deep learning (DL), and natural language processing (NLP), has demonstrated the ability to process large, complex datasets and identify hidden patterns^16,17. Applications in pharmaceuticals range from virtual screening of chemical libraries, prediction of binding affinities, biomarker identification, toxicity prediction, and optimization of molecular properties, to clinical trial design and patient stratification^8,18. In drug delivery, AI contributes to optimizing dosage forms, predicting stability, and guiding nanoparticle or lipid-based carrier design⁷ . Nevertheless, AI is not without limitations. Its predictive performance is highly dependent on the quality and diversity of training datasets. Issues such as algorithmic bias, interpretability, and the “black box” nature of deep learning models often necessitate human expertise to validate and interpret findings⁹. For example, docking simulations may predict binding but still result in non-functional or inactive molecules, highlighting the need for critical evaluation and experimental cross-verification^19,20.

Various AI models have been adopted in pharmaceutical development. Supervised learning uses labeled datasets to predict outputs such as molecular activity or patient outcomes, while unsupervised learning identifies natural groupings within data, such as patient subtypes or compound clusters. Reinforcement learning has recently gained traction in molecular design, where algorithms iteratively optimize structures for improved drug-likeness²¹. Together, these models demonstrate the versatility of AI, though their integration into pharmaceutical pipelines requires careful calibration of algorithm choice, interpretability, and regulatory compliance. Overall, while AI cannot fully replace human judgment in drug discovery and development, it provides an essential decision-support system that complements experimental science. With continued advances in data quality, algorithmic transparency, and regulatory acceptance, AI is expected to become a cornerstone of future pharmaceutical innovation.

Role of Artificial Intelligence and Machine Learning in Drug Efficacy and Toxicity:

AI and machine-learning (ML) methods let researchers extract patterns from large, heterogeneous datasets (chemical structures, bioassays, omics, clinical metadata) that are difficult for traditional rule-based approaches to capture²² .This enables faster virtual screening, more accurate prediction of off-target effects, and early triage of unsafe candidates reducing time, cost, and animal use in preclinical pipelines^6,23.Common approaches include classical ML (random forests, support-vector machines), deep learning (graph neural networks, convolutional and transformer models), and ensemble methods. Success depends heavily on how molecules and biological contexts are represented: molecular descriptors, fingerprints, graph representations of molecules, and learned embeddings from deep nets (e.g., message-passing GNNs) are widely used to encode chemical information for models that predict both efficacy (e.g., potency, target engagement) and toxicity endpoints^4,24.

ML models help predict drug–target interactions, drug sensitivity (e.g., in cancer cell lines), and phenotype-level responses by integrating target biology and compound features. By learning mappings from chemical structure plus disease/biomarker data to response metrics, ML supports candidate prioritization and can suggest mechanism-informed leads that are more likely to produce the desired therapeutic effect in vivo. However, reliable efficacy prediction often requires rich biological context (cell type, pathway state, genetic background), which is still a major data bottleneck²⁵. Toxicity is multifaceted (hepatotoxicity, cardiotoxicity, Geno toxicity, immunotoxicity, etc.). ML models trained on public assays (e.g., Tox21), curated toxicity databases, in vitro readouts, and adverse event records have shown promising accuracy for many endpoints. Recent advances include models that combine chemical structure with transcriptomic or high-content imaging signatures to predict mechanism-specific toxicities more reliably than structure-only models. The ACS JCIM review summarizes many such advances and highlights that AI can effectively integrate multi-modal data to flag compounds with high toxicity risk early²³. Beyond binary prediction, newer ML approaches aim to be interpretable for example, by identifying molecular substructures, predicted off-targets, or pathway perturbations linked to adverse outcomes. Interpretability is key for regulatory acceptance and for guiding medicinal chemistry decisions to reduce liabilities. Nonetheless, interpretability remains an active research area: many high-accuracy models are still black boxes and require post-hoc analyses to be actionable²⁶.

Figure 2 - Various applications of artificial intelligence in pharmaceutical sciences.

Role of Collaboration between Ai-Ml Researchers and Pharmaceutical Scientists:

Collaboration between artificial intelligence (AI) researchers and pharmaceutical scientists is essential for accelerating drug discovery and improving the development of safe and effective therapeutics⁴. By combining expertise in computational modeling with deep domain knowledge in pharmacology and medicinal chemistry, these interdisciplinary teams can design and implement machine learning models that are both biologically relevant and computationally robust²⁷. Such collaboration enables the integration of diverse datasets including chemical structures, omics data, clinical trial outcomes, and real-world patient information allowing AI models to predict drug efficacy, optimize lead compounds, and anticipate potential toxicities with greater accuracy. Furthermore, AI can assist in rationalizing clinical trial designs by identifying patient subgroups likely to respond to specific therapies, thereby enhancing trial efficiency and reducing costs. Collaborative efforts also foster the development of explainable AI models, where insights into molecular mechanisms, off-target effects, and pharmacokinetic behaviors can inform experimental validation and regulatory approval processes. This synergy not only accelerates the timeline from target identification to market but also contributes to the advancement of personalized medicine by tailoring treatments to individual genetic and phenotypic profiles. Overall, the integration of AI into pharmaceutical research through strong interdisciplinary collaboration enhances innovation, reduces development costs, and improves patient outcomes by combining computational power with experimental insight^23,28,29.

Ethical Consideration Regarding the Use of Ai-Ml in the Pharmaceutical Industry:

The integration of artificial intelligence (AI) into the pharmaceutical industry has brought significant ethical challenges that require careful attention to ensure responsible and equitable implementation²⁷. A cross-sectional study conducted among 501 pharmacy professionals in the Middle East and North Africa (MENA) region revealed multiple concerns related to AI adoption in pharmacy practice. Privacy and security of patient data emerged as a major issue, with nearly 59% of respondents expressing apprehension about the handling of sensitive health information by AI systems. Beyond data protection, a substantial proportion of participants 62.9% feared that AI-driven automation could lead to job displacement, while 67% highlighted the lack of clear legal and regulatory frameworks as a barrier to safe and effective AI deployment. These findings underscore the urgent need for robust data governance, clear ethical guidelines, and workforce adaptation strategies. Ethical principles such as informed consent, beneficence, non-maleficence, justice, and transparency are paramount in guiding AI implementation. Ensuring that patients are adequately informed and consent to AI-assisted decisions not only respects their autonomy but also promotes trust in healthcare systems. Furthermore, collaboration among AI developers, pharmaceutical scientists, healthcare providers, and regulatory authorities is critical to establish standardized ethical frameworks, develop educational programs, and create protocols that mitigate risks associated with AI integration. Such interdisciplinary efforts can help balance innovation with patient safety, ultimately improving healthcare outcomes while maintaining ethical standards in AI-driven pharmaceutical research and practice³⁰.

Case Studies:

Case Study 1: AlphaFold for Protein Structure Prediction- One of the most groundbreaking applications of AI in drug discovery is AlphaFold, developed by DeepMind. AlphaFold employs deep learning to predict the three-dimensional structures of proteins directly from their amino acid sequences with unprecedented accuracy. A notable case study involved Cyclin-dependent Kinase 20 (CDK20), a protein with very limited experimental structural data available. Using AlphaFold, researchers predicted the 3D structure of CDK20, which provided critical insights into its functional domains and potential ligand-binding sites. This predicted structure was then used to guide the design and virtual screening of small-molecule inhibitors targeting CDK20. By enabling structure-based drug design for a protein that lacked experimentally determined structures, AlphaFold demonstrated how AI can overcome a major bottleneck in early-stage drug discovery, accelerating the identification of potential therapeutic candidates and reducing the need for costly and time-consuming laboratory experiments³¹.

Case Study 2: AI-Driven Drug Repurposing for COVID-19- AI and ML have also been extensively applied in drug repurposing, allowing existing drugs to be evaluated for new therapeutic indications. During the COVID-19 pandemic, AI-based platforms analyzed the molecular features of the SARS-CoV-2 virus, including protein structures and functional pathways, to identify existing drugs that could inhibit viral replication³². One example involved analyzing a library of approved antivirals and immunomodulators to predict which compounds could interact with the viral main protease or RNA-dependent RNA polymerase. AI algorithms highlighted several candidates, including remdesivir and baricitinib, as potential treatments. This approach significantly accelerated the identification of therapeutics compared to traditional experimental screening, demonstrating the efficiency of AI-driven repurposing strategies in responding to emergent health crises. Moreover, this case emphasized how AI can integrate diverse data sets such as viral protein structures, drug-target interactions, and clinical data—to make predictions that are both biologically relevant and actionable³³.

Case Study 3: AI in Cancer Drug Repurposing:

In oncology, AI has been used to match existing drugs with specific molecular profiles of cancer types. Researchers applied machine learning models to analyze large datasets comprising genomic, transcriptomic, and proteomic profiles of various tumors. By correlating the molecular characteristics of cancer cells with the known mechanisms of action of approved drugs, AI systems were able to identify non-oncology drugs with potential anti-cancer activity. For example, certain anti-inflammatory or cardiovascular drugs were predicted to inhibit key signaling pathways in specific tumor types, leading to experimental validation studies. This approach not only reduces development time and costs but also opens new therapeutic options for patients by repurposing drugs whose safety profiles are already well established. The case highlights how AI-driven repurposing can transform precision oncology by tailoring treatments to molecularly defined patient subgroups³⁴.

Case Study 4: Multi-Omics Integration for Chronic Disease Biomarkers: In the study highlighted by Ogunjobi et al., machine learning (ML) models were applied to integrate genomic, transcriptomic, proteomic, and metabolomic data from patients with chronic diseases such as type 2 diabetes and cardiovascular disorders. By analyzing these multi-omics datasets, supervised learning algorithms identified patterns correlating specific molecular profiles with disease onset and progression. This allowed the discovery of predictive biomarkers that could indicate early disease risk and stratify patients for personalized interventions. The ML-driven approach enabled the simultaneous consideration of thousands of molecular features, revealing biomarkers that traditional statistical methods might overlook³⁵.

Case Study 5: Nonparametric Bayesian Learning for Clinical Trial Design and Analysis- A notable application of nonparametric Bayesian methods in clinical trial design is the study by Xu et al., which proposed a Bayesian nonparametric utility-based group sequential design for a randomized clinical trial comparing a gel sealant to standard care for resolving air leaks after pulmonary resection. The challenge addressed was the skewed and multi-modal distribution of resolution times, making traditional mean-based analyses inadequate. By employing Bayesian nonparametric probability models, the study utilized weighted means, with weights elicited as clinical utilities of resolution times, to inform the comparative test. The design incorporated posterior expected utilities as group sequential test criteria, allowing for interim analyses and decisions based on accumulating data. Simulation studies demonstrated the procedure's frequentist properties, ensuring robust decision-making throughout the trial³⁶.

Case Study 6: Machine Learning for Precision Medicine: Machine learning (ML) has emerged as a powerful tool in precision medicine, enabling the analysis of complex, high-dimensional biological data to guide personalized treatment strategies. In the study reviewed by MacEachern, ML techniques were applied to large-scale genetic and genomic datasets to identify patterns associated with disease susceptibility, progression, and treatment response. Supervised learning models were used to predict patient outcomes based on genomic profiles, while unsupervised clustering techniques helped stratify patients into subgroups with similar molecular and clinical characteristics. The study demonstrated that integrating multiple ML approaches can reveal biomarkers and molecular signatures that inform individualized therapeutic decisions. For example, by analyzing gene expression patterns and single-nucleotide polymorphisms, ML models could identify patient subpopulations likely to benefit from targeted therapies, thus optimizing treatment efficacy and minimizing adverse effects. Moreover, the study emphasized that the iterative training of ML models with continuously updated patient data enhances predictive accuracy over time, facilitating adaptive and responsive clinical decision-making. Overall, this case highlights how ML can transform precision medicine by leveraging computational power to uncover clinically actionable insights from complex genomic data, ultimately improving patient outcomes and advancing personalized healthcare³⁷.

Challenges and Limitation of Using Artificial Intelligence and Machine Learning in Drug Discovery:

The application of AI and machine learning in predicting drug efficacy and toxicity also faces several challenges and limitations. One major issue is data quality and bias, as public and proprietary datasets often vary in reliability, class balance, and experimental conditions, which can lead to models trained on biased data performing poorly when generalized to new compounds. Another challenge is out-of-domain generalization; ML models may fail when encountering chemo types or biological contexts that were not represented in the training data, limiting their applicability to novel chemical spaces. Endpoint heterogeneity also complicates model development and benchmarking, since varying definitions and measurement protocols for toxicity endpoints make it difficult to compare or integrate results across different studies. In addition, regulatory and validation hurdles pose significant constraints, as agencies require rigorous model validation, interpretability, and transparency before AI-driven predictions can be used in decision-making workflows, and integrating these models effectively demands adherence to standards, reproducibility, and prospective validation to ensure reliability and safety²³.

REFERENCES:

1. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ. 2016 May 1; 47:20-33.

2. Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020 Mar 3;323(9):844-53.

3. Kolluri S, Lin J, Liu R, Zhang Y, Zhang W. Machine learning and artificial intelligence in pharmaceutical research and development: a review. AAPS J. 2022 Jan 4;24(1):19.

4. Patel SS, Shah SA. Comprehensive Overview and its Pharma Application. Asian Journal of Pharmacy and Technology. 2022 Dec 1;12(4).

5. Fatima MJ, Parthiban C. Artificial intelligence [AI]-The game changer in pharmaceutical industry. Asian Journal of Pharmacy and Technology. 2024;14(4):386-94.

6. Bairagi A, Singhai AK, Jain A. Artificial intelligence: Future aspects in the pharmaceutical industry an overview. Asian Journal of Pharmacy and Technology. 2024;14(3):237-46.

7. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discov Today. 2018 Jun 1;23(6):1241-50.

8. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019 Mar 1;24(3):773-80.

9. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016 Jul 7;375(1):65-74.

10. Makady A, de Boer A, Hillege H, Klungel O, Goettsch W. What is real-world data? A review of definitions based on literature and stakeholder interviews. Value Health. 2017 Jul 1;20(7):858-65.

11. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nat Biomed Eng. 2018 Oct;2(10):719-31.

12. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019 Jan;25(1):44-56.

13. Walsh G. Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018 Dec;36(12):1136-45.

14. Ecker DM, Jones SD, Levine HL. The therapeutic monoclonal antibody market. In: MAbs. 2015 Jan 2 (Vol. 7, No. 1, pp. 9-14). Taylor & Francis.

15. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021 Dec;6(12):1078-94.

16. LeCun Y, Bengio Y, Hinton G. Deep learning. Nature. 2015 May 28;521(7553):436-44.

17. Patel AI, Khunti PK, Vyas AJ, Patel AB. Explicating artificial intelligence: Applications in medicine and pharmacy. Asian Journal of Pharmacy and Technology. 2022;12(4):401-6.

18. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, Li B, Madabhushi A, Shah P, Spitzer M, Zhao S. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019 Jun;18(6):463-77.

19. Walters WP, Barzilay R. Applications of deep learning in molecule generation and molecular property prediction. Acc Chem Res. 2020 Dec 28;54(2):263-70.

20. Patil P, Nrip NK, Hajare A, Hajare D, Patil MK, Kanthe R, Gaikwad AT. Artificial intelligence and tools in pharmaceuticals: An overview. Research Journal of Pharmacy and Technology. 2023;16(4):2075-82.

21. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv. 2018 Jul 25;4(7): eaap7885.

22. Shukla SL, Behere SE. Artificial Intelligence in Pharmacology Research. Research journal of Pharmacology and Pharmacodynamics. 2025;17(1):59-68.

23. Tran TT, Surya Wibowo A, Tayara H, Chong KT. Artificial intelligence in drug toxicity prediction: recent advances, challenges, and future perspectives. J Chem Inf Model. 2023 Apr 26;63(9):2628-43.

24. Tsou LK, Yeh SH, Ueng SH, Chang CP, Song JS, Wu MH, Chang HF, Chen SR, Shih C, Chen CT, Ke YY. Comparative study between deep learning and QSAR classifications for TNBC inhibitors and novel GPCR agonist discovery. Sci Rep. 2020 Oct 8;10(1):16771.

25. Badwan BA, Liaropoulos G, Kyrodimos E, Skaltsas D, Tsirigos A, Gorgoulis VG. Machine learning approaches to predict drug efficacy and toxicity in oncology. Cell Reports Methods. 2023 Feb 27;3(2).

26. Habeeba, S. Use of artificial intelligence in drug discovery and its application in drug development.2023.

27. Kakade PA, Sontakke SM, Hosmani AH, Gonjari ID. The Impact of Artificial Intelligence on Pharmacy Education, Research and Practice. Asian Journal of Pharmaceutical Research. 2025 Jul 17;15(3):327-32.

28. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, Garcia-Fandino R. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023 Jun 18;16(6):891.

29. Ingale S, Shrisunder N, Gophane G, Birajdar A. Ascent of artificial intelligence (ai) in pharmacy. International Journal of Technology. 2024;14(1):54-8.

30. Hasan HE, Jaber D, Khabour OF, Alzoubi KH. Ethical considerations and concerns in the implementation of AI in pharmacy practice: a cross-sectional study. BMC Med Ethics. 2024 May 16;25(1):55.

31. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, Tunyasuvunakool K, Bates R, Žídek A, Potapenko A, Bridgland A. Highly accurate protein structure prediction with AlphaFold. Nature. 2021 Aug 26;596(7873):583-9.

32. Zaeri N. Drug discovery for COVID-19 and related mutations using artificial intelligence. Research Journal of Pharmacy and Technology. 2023;16(11):5384-91.

33. Liu Z, Chen X, Carter W, Moruf A, Komatsu TE, Pahwa S, Chan-Tack K, Snyder K, Petrick N, Cha K, Lal-Nag M. AI-powered drug repurposing for developing COVID-19 treatments. Reference Module in Biomedical Sciences. 2022 Feb 23: B978-0.

34. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019 Jan;18(1):41-58.

35. Ogunjobi TT, Gbayisomore TJ, Nneji PO, Olofin OO, Olowe EN, Gigam-Ozuzu CD, Afolabi JI, Okwuokei NB, Boluwaji VA, Ojeniran TP, Ogini IO. Environmental epigenetics and its impacts on disease susceptibility: a comprehensive review. Medinformatics. 2024 Aug 8.

36. Liu GF, Han B, Zhao X, Lin Q. A comparison of frequentist and Bayesian model-based approaches for missing data analysis: case study with a schizophrenia clinical trial. Stat Biopharm Res. 2016 Jan 2;8(1):116-27.

37. MacEachern SJ, Forkert ND. Machine learning for precision medicine. Genome. 2021;64(4):416-25.

Received on 06.10.2025 Revised on 14.11.2025

Accepted on 20.12.2025 Published on 31.01.2026

Available online from February 07, 2026

Asian J. Research Chem.2026; 19(1):25-30.

DOI: 10.52711/0974-4150.2026.00006

This work is licensed under a Creative Commons Attribution-Non Commercial-Share Alike 4.0 International License. Creative Commons License.